Serenex
Durham · Founded 2000
About Serenex
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.
Company Facts
- Founded: 2000
- Legal name: Serenex, Inc.,
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $86.0M
- Funding stage: M&A
- Last round: Series D (Jun 2007)
- Website: serenex.com
- Phone: +1 919281-6001
Canonical: https://fsome.com/organization/serenex-8353611 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.